Imugene Limited (IMU:ASX)

10.0¢

right-arrow Created with Sketch. -0.005 (-4.76%)
MCAP $499.7M
Last trade 13.42pm 26/02/2021 20mins delayed

Latest Announcements

23/02/2021IMUImugene Limited
602
MCap
23/02/2021IMUImugene Limited
12/02/2021 Price SensitivePSIMUImugene Limited
03/02/2021IMUImugene Limited
581
MCap
03/02/2021IMUImugene Limited
29/01/2021 Price SensitivePSIMUImugene Limited
27/01/2021IMUImugene Limited
541
MCap
27/01/2021IMUImugene Limited

Company Overview

Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.

IMU in the news

Search Previous Announcements